

NOTICE OF THE EXTRAORDINARY GENERAL MEETING IN LIDDS AB (publ)

The shareholders in LIDDS AB (publ) (reg. no. 556580-2856) (the “Company” or “LIDDS”) are hereby convened to the Extraordinary General Meeting in the Company’s premises at Uppsala Business Park with visiting address Rapskatan 7, Uppsala, on Tuesday 9 January 2024 at 11.00 (CET).

Right to participate and registration

Right to participate at the Extraordinary General Meeting is held by those shareholders who are registered in the share register held by Euroclear Sweden AB on Friday 29 December 2023 and who have given notice to the Company no later than Wednesday 3 January 2024 in writing to LIDDS AB (publ), Virdings Allé 32B, 754 50 Uppsala or by email to info@liddspharma.com.

The notification should state full name, personal code number or corporate ID number, shareholding, address, daytime telephone number and also details of deputy when applicable. When applicable, power of attorney, registration certificates and other authorisation documents should be appended to the notification.

Nominee-registered shares

To be entitled to participate in the Extraordinary General Meeting, shareholders whose shares are held in the name of a nominee must, in addition to providing notification of their participation in the Extraordinary General Meeting, re-register the shares in their own name so that the shareholders are registered in the share register on the record date on 29 December 2023. This re-registration may be temporary (so-called “voting right registration”) and is carried out through the nominee according to their procedures at a time predetermined by the nominee. Voting rights registration that has been completed by the nominee no later than 3 January, are considered when preparing the share register.

Proxy

Shareholders represented by proxy shall issue dated and signed power of attorney for the proxy. Power of attorney must be provided no later than at the meeting, but preferably through prior submission of a copy. If the power of attorney is issued by a legal entity, attested copies of the certificate of registration (or equivalent document for foreign legal entity), must be appended to the power of attorney. The power of attorney’s period of validity must be a maximum of five years if specifically indicated. If no period of validity is indicated, the power of attorney applies for a maximum of one year. The company provides a proxy form on the company’s website www.liddspharma.com and a proxy form is also sent to those shareholders who request one and provide their address.

Number of shares and votes

As per 15 December 2023, there are a total of 68,231,663 shares and votes in the Company. The Company holds no own shares.

Proposed agenda

1. Opening of the Meeting and election of Chairman of the Meeting.
2. Preparation and approval of the voting list.
3. Approval of the agenda.
4. Election of one or two persons to verify the minutes.
5. Determination of whether the Meeting has been duly convened.
6. Determination of the number of Board members and deputy Board members.
7. Determination of remuneration to the Board of Directors.
8. Election of Board members and deputy Board members.
9. Closing of the meeting.

Proposed resolutions

The nomination committee intends to present proposals in accordance with item 6-8 at the latest in connection with the Extraordinary General Meeting.

The current board members will place their board seats at disposal.

Information at the Extraordinary General Meeting

The Board of Directors and the CEO shall at the request by a shareholder and provided that it can be done without material damage to the Company, at the Extraordinary General Meeting disclose information regarding circumstances that may affect the assessment of an item on the agenda for the Extraordinary General Meeting. Shareholders wishing to submit questions in advance may send them to LIDDS AB (publ), Attn. Jenni Björnulfson, Virdings Allé 32B, 754 50 Uppsala or by e-mail to info@liddspharma.com.

Processing of personal data

For information on how your personal data is processed, see the integrity policy that is available at Euroclear's webpage, <https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf>.

Uppsala in December 2023
LIDDS AB (publ)
The Board of Directors

For additional information, please contact

Jenni Björnulfson, CEO and CFO
Phone: +46 (0)70 855 38 05
E-mail: jenni.bjornulfson@liddspharma.com

Pontus Ottosson, Chairman of the Board
Tel: +46 (0)70 535 93 34
E-post: po@anprima.se

LIDDS' Certified Adviser is Redeye AB

LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and can solve problems within many indication areas, mainly within oncology. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage clinical phase, and projects about to enter clinical development. The company is listed on Nasdaq First North Growth Market.

Attachments

NOTICE OF THE EXTRAORDINARY GENERAL MEETING IN LIDDS AB (publ)